Loading...
•
Mar 31, 2021
iBio Q3 2021 Earnings Report
iBio reported an increase in revenue and a net loss for the fiscal third quarter ended March 31, 2021.
Key Takeaways
iBio reported its Q3 2021 financial results, with revenue increasing to $0.8 million compared to $0.1 million in the same period last year. The company's net loss was $7.7 million, or $0.04 per share, compared to a net loss of $4.7 million, or $0.06 per share, in the same period of 2020.
Revenue increased to $0.8 million, up from $0.1 million year-over-year.
Cost of Goods Sold was $0.5 million, resulting in a gross profit of $0.3 million.
Net loss attributable to iBio stockholders was $7.7 million, or $0.04 per share.
Cash, cash equivalents, and debt investments totaled $103.9 million as of March 31, 2021.
iBio
iBio
Forward Guidance
iBio believes it will have sufficient resources to fund its planned operations at least through March 31, 2023, inclusive of its planned investment in the FastPharming Discovery Platform and potential in-licensing activities.